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In the debate about whether to return individual genetic results to research participants,
consideration of the nature of results has taken precedence over contextual factors associated with
different study designs and populations. We conducted in-depth interviews with 24 individuals
who participated in a genotype-driven study of cystic fibrosis: 9 of the individuals had cystic
fibrosis, 15 had participated as healthy volunteers, and all had gene variants of interest to the
researchers. These interviews revealed that the two groups had different ideas about the
meaningfulness of genetic results. Our findings point to the importance of understanding research
context, such as participants’ relationship with the researcher and whether they have the disease
condition under study, when considering whether to return individual results.
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In the field of human genetic research, much debate has been generated concerning the
return of individual results to research participants. Recommendations on return of results
have been issued by the National Heart, Lung, and Blood Institute and the National
Bioethics Advisory Commission (Bookman et al., 2006; Fabsitz et al., 2010; NBAC, 1999),
and the topic addressed by many respected bioethicists, clinicians, and scientists. Although
this debate has highlighted a number of important features related to the research results
themselves, few have also taken into consideration factors associated with different study
designs and study populations (Beskow & Burke, 2010; Hoeyer, 2010). For example,
researchers may have different responsibilities toward or choose to share different kinds of
information with participants who have been diagnosed with a serious condition, or
participants with whom they have an ongoing relationship or interactions (Beskow & Burke,
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2010). As researchers and ethics boards are increasingly called upon to make case-by-case
decisions about whether and how to return different kinds of results, they will likely need to
consider a more nuanced range of factors beyond the nature of the results themselves.
Genotype-driven research recruitment presents particular challenges with regard to return of
results. Such recruitment is driven by genotypic rather than phenotypic information about an
individual. The prospective participant often has no prior knowledge of the genetic
information of interest, which is typically a research-generated finding from a prior study.
Thus, researchers must decide whether to disclose the genetic inclusion criteria that make
individuals eligible when recruiting them for the follow-up study.
The research presented below was part of a larger three-site study exploring participants’
perspectives on genotype-driven research recruitment (Beskow et al., 2011). Specifically,
we interviewed two groups of research participants (patients with cystic fibrosis, selected
from a prior genetic study, and healthy volunteers, selected from a genetic biobank) who
took part in a genotype-based cystic fibrosis study, and who were both informed, as part of
recruitment, that they had one of two genetic variants under study. In this paper, we examine
the different ways that these two groups conceptualized genetic research results as
meaningful, and, in turn, the ways that their preferences for receiving those results differed.
Recommendations on the return of genetic research results related to serious medical
conditions have usually considered two main characteristics of the results: validity and
utility (Bredenoord, 2011; Dressler, 2009). The validity of results refers not only to analytic
validity—the certainty with which researchers identify a particular genetic trait in a subject;
but also to clinical validity—the strength of that trait’s connection with a clinical outcome.
Utility refers to the usefulness of those results. Results may have clinical utility (useful to
inform risk reduction strategies or to improve health outcomes), personal utility (useful for
personal or familial reasons, such as retirement planning or other future decision-making),
personal meaning (the value of knowledge for its own sake), or some combination of the
three (Beskow & Burke, 2010). All of these considerations are important when making
decisions about the return of results in biomedical research, and the meanings of all of these
have been contested (Bredenoord, 2011). Indeed, the very definition of “research results” is
the subject of debate (Miller et al., 2008), along with what constitutes a “meaningful result”
for patients (Miller, Hayeems, & Bytautas, 2010; Trinidad et al., 2011). In the case of
genetic research, decisions may be even more complex, as genetic results may reveal
unexpected or unwanted information about family members (Bredenoord, 2011; Dressler,
2009).
In a recent commentary, Beskow and Burke (2010) note that research populations may have
differing levels of vulnerability in terms of their health status; differing depths of
relationship with ongoing research or particular researchers; and differing degrees of
dependence on research for access to genetic information. These characteristics, they argue,
shape the context of research and should be taken into account when considering the return
of genetic results. In addition, recent reports have documented participants’ stated desire for
the return of individual results (Murphy et al., 2008; Fisher, 2008; Miller, Hayeems, &
Bytautas, 2010; Michie et al., 2011), or even an expectation that researchers are obliged to
share important findings with them (Cadigan & Davis, 2009). This study offers an
opportunity to compare the experiences and perspectives of two research populations who
had been given identical information during genotype-driven research recruitment for the
same study, yet conceptualized genetic research results differently in light of their very
different contexts.
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For this qualitative study of participants’ perspectives on genotype-driven recruitment,
interviews were conducted with individuals who had participated in a study about
circulating levels of the protein TGFβ1 (see Figure 1). Individuals were selected for this
study based on the presence of particular genetic traits suspected to play a role in circulating
blood levels of TGFβ1, which in turn have been shown to affect lung function in individuals
with cystic fibrosis (Cutting, 2010; Drumm et al., 2005). Half of the TGFβ1 study
participants were individuals with cystic fibrosis who had participated in an earlier study of
genetic modifiers of cystic fibrosis headed by the same investigator. Most of these
participants had been with the same doctor or team of doctors for much of their lives, and
virtually all were routinely asked to participate in research studies in the clinic. The other
half of the TGFβ1 participants were individuals without cystic fibrosis who were recruited
from a genetic biobank, the Environmental Polymorphisms Registry (EPR), which serves as
a resource for researchers seeking to study particular genetic traits (Chulada et al., 2008).
For our qualitative interviews, we recruited participants with and without cystic fibrosis
from the TGFβ1 (“followup”) study. Principal investigators from the “original” studies (the
cystic fibrosis genetic modifiers study and the genetic biobank) sent letters on our behalf to
participants from each study who had also participated in the TGFβ1 study. Response cards
and stamped envelopes were included so that interested individuals could contact us directly.
All interviews were conducted in person at a location of the respondent’s choosing, with the
exception of one interview that was conducted by telephone because the respondent lived
over 60 miles from the study site. Prior to the start of the recorded interview, all participants
provided verbal consent to participate. Cadigan and Michie conducted all of the interviews.
This study was determined exempt by the Duke University Health System (DUHS)
Institutional Review Board (IRB), the institution at which this multi-site study was based.
The IRB at The University of North Carolina at Chapel Hill (the site responsible for
recruiting the above participants and conducting interviews) agreed to rely on the DUHS
IRB’s decisions.
Genotype-Driven Recruitment Process for the TGFβ1 Study
Cystic fibrosis (CF) participants were recruited for the TGFβ1 study at a clinical visit,
during which a researcher explained the study to them. Biobank participants were asked to
join the TGFβ1 study via a letter that outlined the goals of the study and explained that
recipients were being recruited because of a trait in their DNA; however, the letter did not
provide any more specific genetic information.
The consent form, which was identical for CF participants and biobank participants, briefly
explained the TGFβ1 protein and previous research related to genes and TGFβ1. It stated,
“Previous studies have shown that in cystic fibrosis (CF) genotypes called CC and TT are
related to different levels of TGFβ1 and how severe the disease is.” The consent form then
offered categorical genetic inclusion criteria for study participants (Box 1).
Box 1
Genetic Inclusion Criteria for TGFβ1 Study
You are being asked to be in the study because you are either:
1 A cystic fibrosis patient who consented to donate blood for research as part
of the Gene Modifier Study. During this study, your blood was tested to
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determine your genotype. You are being asked to participate in this study if
you have either the CC or the TT genotype.
OR
2 You are someone who has consented to donate blood as part of the
Environmental Polymorphisms Registry (EPR). For this study, a sample of
your blood was collected and stored for possible future research studies. You
are being asked to participate in this study because you also have the CC or
TT genotype, but do not have cystic fibrosis. [emphasis in original]
During the first few interviews it became clear that virtually none of the participants recalled
reading this passage, and that most did not understand that they were asked to join the
TGFβ1 study because a previous study had identified a particular trait in their genotype.
Hence, for a subset of the interviews, we added a brief interaction at the end of the protocol
in which we showed participants a consent form identical to the one they signed for the
TGFβ1 study, highlighting the above passage that explained the genetic inclusion criteria.
Interviewers asked participants to read this passage, discussed their reactions to it, and asked
them to revisit some of the earlier interview topics with this information in mind.
Interview Topics
Interviewees were asked to recall their experiences of both the original study (either the
cystic fibrosis genetic modifiers study or joining the biobank) and the followup study (the
TGFβ1 study), and provided opinions on the return of individual genetic research results in
the context of recontact for a genotype-driven follow-up study (see Beskow et al., 2011, for
more detailed information about the interview protocol). The analysis presented here focuses
on interviewees’ comments about the return of individual genetic research results in the
context of genotype-driven recruitment. Although participants had been told only that they
had one of two genetic traits (not which one) during recruitment and the consent process for
the TGFβ1 study, and rarely recalled receiving any genetic information at all, the topic of
individual results was a rich one in our interviews. All respondents provided comments
about the nature of individual results and the circumstances under which they should be
offered. These discussions usually occurred in response to a set of questions on these topics,
but also sometimes arose spontaneously during other parts of the interview. At the beginning
of this set of questions, interviewees were read a definition of individual genetic research
results (Box 2) in order to ensure they were given identical information.
Box 2
Definition of Individual Genetic Research Results
Researchers doing a genetic study are usually trying to find out whether there is a link
between a genetic trait and the medical condition they are studying. By looking at the
DNA from everyone in the study, researchers are sometimes able to find such a trait.
Some people in the study have that particular trait and some people don’t. Also,
researchers sometimes know something about that genetic trait and what it might mean—
but often they are not sure what it means or if it is even related to the medical condition
until they do more studies. So, when I say, “individual genetic research results,” I mean
information about whether or not you have the genetic trait that researchers identified in
their study.
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All interview recordings were transcribed and identifying references redacted. Transcripts
were imported into QSR International’s NVivo 8 qualitative data analysis software. Through
a collaborative process with the other two sites in the larger study (Beskow et al., 2011), a
codebook was created. All transcripts from UNC’s site interviews were coded by Cadigan
and Michie using this codebook. Twenty percent of the transcripts were coded by both
coders and any discrepancies were resolved by consensus (Miles & Huberman, 1994).
Cadigan and Michie then examined more closely the responses to the series of interview
questions concerning individual research results. They read these interview segments aloud
to one another, noting similarities and differences between these responses. Similarly, these
segments were compared to the interview addendum in which 14 interviewees were asked to
read and respond to the section of the TGFβ1 consent form. From these detailed
examinations, they compiled a list of the characterizations interviewees provided of
individual research results, and a list of circumstances under which these participants said
that individual research results should or should not be returned to study participants. These
two lists were developed in an iterative fashion as new segments were read and analyzed and
compared with previous read segments (Charmaz, 2006). The resulting categories were then
compared against text related to the nature of individual results or of preferences for return
of results, as coded in NVivo.
Results
All participants in our interview study were White and non-Hispanic, reflecting the racial
and ethnic composition of the TGFβ1 study population. Overall, the respondents were well-
educated (Table 1), particularly the biobank participants. The biobank’s original recruitment
base included regional universities and research-related entities; thus, several of the biobank
participants were themselves scientific researchers or physicians, or had previously worked
in scientific research positions.
How Meaningful Are Individual Genetic Research Results?
Though our interview protocol did not specifically ask respondents about their perceptions
of meaningfulness of individual genetic research results, our analysis of the interviews
indicates that both biobank and CF participants assumed a degree of meaningfulness not
necessarily implied by the text of the definition we offered (Box 2). The two groups differed
regarding the meanings they offered for research results, although both groups invoked
validity and/or utility.
Biobank Participants—Biobank participants’ perceptions of meaningfulness of
individual results often included an assumption of truth or “real knowledge,” and an
assumption that the results would contain “bad news” or negative information.
“Real Knowledge”: Despite our definition of individual genetic research results
emphasizing that researchers often are not sure what results mean or if they are related to the
medical condition under study, many biobank participants assumed that individual genetic
results would offer conclusive “truth” and that researchers would understand the
implications of the result. For example, one biobank participant remarked:
Why would an investigator not communicate the results? [Interviewer gives
example of researchers not knowing what results mean yet.] But I was assuming
that they knew. That their data was definitive. If the data’s not conclusive, you
shouldn’t share that with anybody. (C19)
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Similar to this participant, many respondents’ assumptions regarding the certainty of results
were brought into focus when they were specifically asked about uncertain results—and this
typically led to a negative opinion about whether such results ought to be returned. When
asked if researchers should offer results that have uncertain meaning, another biobank
participant responded, “No. Those are not real knowledge. It’s not truth yet. It’s a
speculation. It’s a hypothesis. It’s a guess. And I don’t think that’s fair to put that in
somebody’s head” (C09).
“Bad News”: In addition to assuming that research results would offer “real knowledge,”
many biobank participants believed that genetic results would convey bad news. Two
respondents (C18 and C22) likened the return of results to opening a “Pandora’s box.”
While some of our interview questions about return of research results referenced
respondents’ actual experiences of being recruited for the follow-up study, some asked
instead for general opinions. In these latter responses, biobank participants’ talk of results
expanded well beyond discussion of cystic fibrosis; they brought up many other serious
medical conditions, such as various forms of cancer, Alzheimer’s disease, and amyotrophic
lateral sclerosis (Lou Gehrig’s disease). Because of their belief that results offered “real
knowledge,” biobank participants often assumed that research results would be valid, robust,
and predictive, indicating their risk of developing a serious medical condition or passing that
condition to their biological children. Almost no one talked about the possibility that
research results might convey good news, such as the presence of a protective genetic trait.
Thus, when asked what results might be beneficial to learn, respondents still responded in
the negative:
…Anything that was abnormal or red flagged on my DNA. Anything that kind of
stood out as like this either is a problem, could potentially be a problem, could be
passed on to my children or anything like that. … that would be beneficial for me
now or later that I might need to go seek medical help with or something like that
or start watching my diet or something like that. That would be important for me to
know. (C12)
Many respondents, like this one, linked the benefit of receiving results to the assumption
that results offer negative, but definitive knowledge. In addition, this respondent went a step
further in assuming utility: she surmised she would be able to get treatment or alter her
lifestyle or know in advance her children’s risk of certain medical conditions.
Some biobank participants seemed to assume that not receiving individual genetic research
results would mean that they are “OK.” If results are bad news, then “no news is good
news.” One respondent, when asked, “How did you feel about not getting individual genetic
research results [when you were contacted about the follow-up study]?” commented:
I think I just kind of assumed that that means I don’t have [abnormal results]. You
know, no news is good news. So it’s the fact that I wasn’t contacted. It’s kind of
like when you go and get like a strep test at the doctor, and they’re like, “We’ll call
you if you have strep. If you don’t hear from us, you don’t.” Kind of like that. Like
if I don’t receive any sort of information, I’m good. (C12)
This respondent, like some others, discussed research results as if they were akin to clinical
test results. Moreover, in response to the question, “How did not getting individual genetic
research results from the first study affect your decision to be in the second study?,” she
noted, “It didn’t because I figured I was clear” (C12).
Thus many biobank participants, who did not have the condition under study and who (as
part of eligibility criteria for the follow-up study) had no other chronic health conditions,
assumed that results would offer real knowledge with definite, negative implications.
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Moreover, for some, not receiving results also had meaning because it indicated that one’s
DNA was “clear” or otherwise good.
Cystic Fibrosis Participants—CF participants’ conceptions of individual genetic
research results were similar to those of biobank participants in that they, too, assumed
meaningfulness of results that was related to validity. However, their responses more often
also invoked utility. CF participants had more flexible standards than biobank participants
for what they would consider useful. These standards focused on the presumption that
results would offer them additional information about their condition, even in the absence of
immediate clinical utility. Unlike biobank participants who conceptualized results to be
about all kinds of possible severe medical conditions, CF participants largely confined their
talk of individual results to results about cystic fibrosis. They strongly believed in both the
promise of research to improve lives for those with cystic fibrosis and the idea that
individual research results would tell them more about their own bodies and condition.
The Promise of Research: In contrast to biobank participants’ assumption that research
would produce results that would be “bad news,” CF participants tended to talk about the
promise of research. They believed research would lead to a cure or improved treatments
and therapies for themselves and the “CF community.” One respondent, when asked why he
participated in the genetic modifiers parent study, commented, “They just came and asked
me if I wanted to participate, and I said ‘Sure. Anything I can do to help out.’ I mean,
finding the cure maybe for cystic fibrosis or helping out with the genes and stuff ” (C02). In
fact, some respondents seemed particularly hopeful about genetic studies of cystic fibrosis.
One respondent remarked:
Any time I’m asked to do a study that focuses on genetic stuff, I’m kind of inclined
to participate because I still kind of like the pie-in-the-sky dream of “Oh, maybe
one day we can have a drug where it just fixes everything.” Instead of, “Oh, we’re
going to treat this little part of your disease, and then we’re going to treat this little
part, and you’re going to have a million different things to keep track of.” So even
though I don’t think right now they’re working as much on a blanket “we’re going
to re-do all your genes” cure, if I can do anything that helps with something
remotely related to that, then I’m inclined to participate. (C06)
Some respondents specifically tied the promise of research to receiving research results. As
one participant noted when asked why researchers should offer individual results:
I just think it’s important for people to know. … I like to know because if there’s
gonna be a new drug to market or something that’s gonna be beneficial to me,
that’s something that I’d want to know. You know, and if it’s not gonna benefit me,
then I’d like to know that, too. (C13)
For this participant, even results with uncertain meaning held promise and were desirable for
that reason:
Well, for me I just like to know that kind of information. Changes, any new
developments, anything that would further another study that I might be able to get
involved in where they could just look into it a little bit further. (C13)
As was the case for many participants with cystic fibrosis, this respondent saw the
possibility of ongoing research participation as part of the road to better treatments for
himself and the entire CF community.
“This is my body and I want to know”: Most CF participants stated that they wanted
individual results. As one participant commented, “This is my body and I want to know”
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(C01). These participants believed that individual results would reveal information about
their bodies, which would be beneficial even if the implications were bad. Some noted they
had already been given the “bad news” that they have cystic fibrosis; more information
could only help to deal with the bad news. As one respondent commented, “I mean it might
be a little depressing [to get unpleasant individual results] … but people know they have CF.
It’s not new” (C06).
Another respondent talked about how she felt pleased to receive an individual result from a
prior research study: “It’s just more of me taking charge of my CF, you know, knowing
about it…. It makes you a part of the process” (C01). For CF participants then, individual
research results offered the opportunity to understand more about their condition which, in
addition to other benefits, was viewed as empowering.
In summary, for CF participants, the meaning of individual research results was different
than for biobank participants. They were interested in individual results because they wanted
information about their bodies and their disease. Like biobank participants, they often
assumed that results would be clinically valid and utilizable. However, having a chronic
condition and believing in the promise of research to help ameliorate that condition meant
they were more comfortable with uncertain research results.
When Should Individual Genetic Research Results Be Given?
Because biobank participants and CF participants had different conceptions of the
meaningfulness of results, they also had different ideas about the circumstances under which
individual research results should be offered to participants.
Biobank Participants—When weighing the risks and benefits of offering results, biobank
participants’ most frequently mentioned risk was worry. Several used the term “freak out”
when discussing how people might react to receiving results. Their concern over people
“freaking out” seemed to follow logically from their assumption that results would be
clinically valid and convey bad news, particularly in the absence of clinical or other utility:
If it’s not actionable, then I don’t see any benefit in telling people. … telling people
when there’s nothing that they can do about it just doesn’t really help. [Interviewer:
Do you see specific problems that might arise?] Freaking people out. You know,
distress. (C05)
However, many biobank participants assumed that results would in fact be associated with
immediate or near-term utility, which balanced their concerns about the risk of distress.
When asked what kind of individual results would cause her concern to learn from a
researcher, one respondent remarked:
Something that I absolutely cannot change…. If you find out that you have
something that’s terminal or something that there’s nothing out there in terms of
medication or help or anything, that’s bad news, and to get that kind of bad news is
disturbing, but I feel it’s their obligation to tell you if that stuff pops up because
then you need to find an intervention to help you. (C12)
This respondent, in working through her answer to the interview question, assumed that the
bad news conveyed by individual research results could be mitigated by a beneficial
intervention and used this assumption to argue that researchers should offer results.
Thus, biobank participants felt more comfortable with researchers offering results that have
utility. To some, utility meant, quite broadly, that they could do something with the results.
In fact, a few participants argued that there was no such thing as no utility; that is, there is
always personal utility. They reasoned that, even without clinical intervention, they might be
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able to marshal resources—by changing their lifestyle or making different life decisions—
after receiving these (presumably bad and definitive) results:
There’s no such thing to me as untreatable. … [K]nowing ten years from now I
may have this disease you can make plenty of plans. … I might want to make sure
that I have all my plans in order, health care proxy taken care of, economic lined
up. I might want to get– what do they call it? The insurance that you can go into a
nursing home. Long-term care. … Well, and you know particularly from a genetic
standpoint you’d want to know. The kids would want to know, and I’d want the
kids to know. If it’s genetically passed, you have a risk. … So even if it’s incurable,
I think it’s of value. (C19)
Another participant answered, when asked what the benefits were of offering individual
results that lacked utility, “Just so the person would be able to plan their life appropriately”
(C22). Though acknowledging that some may suffer anxiety from getting such results, he
commented that the good of being able to plan for the future “outweighs the bad” (C22).
Thus biobank participants viewed disclosure of research results as appropriate whenever
utility—in the form of available medical treatments or personal actions—outweighed the
worry associated with disclosure of research results. They would not expect researchers to
disclose results that did not provide utility, since these could only provoke worry.
Cystic Fibrosis Participants—Both biobank and CF participants presumed the clinical
validity of research results. However, for CF participants, the utility of the results was not as
determinate of whether they should be offered as it was for biobank participants. Because
CF participants believed that results offered information about their bodies and their
condition, they wanted them. Moreover, because of their belief in the promise of research,
they expected that even results that are not useful now could be useful in the future. As one
respondent explained:
I mean if they find something like totally unexpected, and they have no idea what it
is, I think they should tell a person. … Maybe they could do more research on the
person and maybe actually find out what’s causing it. [Interviewer: Are there any
problems you can think of with giving people those kinds of individual genetic
research results?] No. I don’t think there’s any problems. I would think it would be
a benefit. Then the person will be more informed if something happens later down
the road to them. (C02)
In general, CF participants were more comfortable than biobank participants with
uncertainty. One respondent, asked why he thought researchers should offer individual
results with uncertain implications, explained:
Just to tell them, I don’t know, “Hey. This might be something that’s wrong, but
we’re not a hundred percent.” Or “This might be why you don’t do so and so or
feel so and so.” I think it’s good to tell everybody everything. [Interviewer: What
do you think the benefit is to those people to find out that information?] To the
person probably nothing. Just the fact of knowing. (C16)
Thus CF participants expressed hope in research and saw receiving results—even results
with uncertain validity and utility—as informing them about their bodies and condition.
Importantly, the CF participants had an existing, and commonly close, relationship with the
researchers—one that was not present for biobank participants. CF participants seemed
comfortable relying on the researcher (who was frequently also their physician) to decide
when results should appropriately be given. Unlike biobank participants, they also had a
strong affinity with a patient community. In the interviews, they acknowledged that they
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participated in studies because they believed the studies may help themselves and/or the “CF
community,” and because they trusted and wanted to help their physician— who is often the
person asking them to participate in the study. This faith in their physicians translated into
faith in them as researchers. As one respondent noted when explaining why she participates
in studies, “If [the physician-researchers] approach me for a research study, then I feel like
it’s for an important cause or an important reason for the condition” (C17).
For many CF participants, attitudes toward receiving individual genetic results from
research studies were bound to their feelings about the physicians and researchers at the
clinic. For example, one respondent, who said she would always prefer to receive genetic
research results, was asked how she felt about not getting individual results. She remarked,
“I was okay with that because I figure if there was anything important worth noting, they
would have been happy to let me know” (C17). Despite their stated desire to receive
meaningful individual research results and a lower threshold for validity and utility, their
trust in the physician-researchers led these participants to defer to those professionals’
decisions on the return of individual results.
Discussion
Our findings suggest that these individuals’ statuses, as patient-participants with a known
genetic disorder or as healthy volunteers without a chronic health condition, informed their
conceptualizations of the meaningfulness of results, their opinions about the return of
individual genetic research results, and their desires for particular types of research results.
We note with interest that virtually no participants recalled receiving genetic information
when recruited for the followup study. Their talk of individual research results in the course
of the interview was based on their assumptions of what results would or should look like.
These views permeated the interviews and seemed to persist despite the definition of
individual genetic research results that we gave immediately before asking for their views
about individual results. Our definition of individual results was meant to convey the
potential ambiguity of research results, and thus it deliberately highlighted that researchers
themselves may not understand the meaning of results. Because many of our biobank
respondents were themselves researchers, we might expect this definition to be particularly
resonant with this group of well-educated and knowledgeable individuals, yet we did not
find that their views were shaped by it.
Equally interesting is our finding that almost no one realized they had participated in a
genotype-driven study and received genetic information as part of their own recruitment.
Even so, our interviews provided rich data about how patient-participants and healthy
volunteers perceive disclosure of results with regard to validity, utility, and personal,
population, and societal implications.
Though our interview protocol did not specifically ask respondents about their perceptions
of meaningfulness of individual genetic research results, the idea that results were
meaningful was an important touchstone for participants as they reflected on the content and
usefulness of such results. While conceptions of meaningfulness differed between the two
groups, it typically invoked some combination of validity and/or utility. Healthy volunteers
commonly equated individual genetic results with the disclosure of bad news. Thus, a
research result was assumed to be valid (real knowledge) and disclosure would be
necessarily tied to “bad news,” while lack of disclosure could imply good news. For those
participants with a known genetic condition (cystic fibrosis), their desire for information
about their bodies and their disease informed their impression that research results would be
meaningful. They often assumed that results would be clinically valid and utilizable.
However, their belief in the promise of research to help ameliorate the condition for
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themselves or others with cystic fibrosis meant they were more comfortable with uncertain
research results. Moreover, unlike biobank participants who assumed results would be bad
news, CF participants had hope that results might offer news that would ultimately benefit
them such as new therapies or a cure (see Tabor et al., 2011, for a similar result among
parents of children with autism).
Second, the meaningfulness assigned to individual genetic results must be understood in the
context of when and how disclosure would occur. Many biobank participants viewed
disclosure of research results as appropriate whenever they perceived that clinical or
personal utility outweighed the worry associated with disclosure of research results. In
contrast, despite their stated desire to receive individual research results and their general
acceptance of a lower threshold of validity and utility, the CF participants trusted their
physician-researchers to decide whether results should be disclosed. It may also be that their
deference to professional judgments influenced their own assessments of the meaningfulness
of results.
Best Practices
The data from these interviews provide participant perspectives to inform policy
recommendations on genotype-driven research recruitment. Importantly, our study includes
two types of research participants who may be targeted for genotype-driven recruitment in
the future: patients with a known genetic condition who consented to at least one prior
genetic research study, and healthy volunteers for a genetic biobank for whom recontact for
additional studies is part of participation in the biobank.
With regard to the issue of whether individual genetic results should be provided as part of
that recruitment, our findings are similar to those found at other sites comprising the larger
study of genotype-driven recruitment (Beskow et al., 2011). Specifically, respondents
advocated a lower threshold for return of individual genetic research than is generally
recommended (Beskow et al., 2011). Yet, as the larger study also reported, ideas varied
between the different study populations regarding the specific circumstances under which
research results should be conveyed as part of that recruitment. These empirical results
support Beskow and Burke’s (2010) suggestion that, in deciding when to offer individual
results, researchers and institutional review boards should consider both the nature of the
results (for example, their validity and utility) and the context (for example, the participant
population and their relationship with the researcher) in which the research is conducted.
Furthermore, our findings suggest the importance of researchers’ awareness of the variety of
meanings participants assign to individual genetic research results. These understandings
and interpretations can lead to different notions about the validity and utility of individual
genetic research results, even among highly educated individuals with significant experience
in research contexts. For this reason, we suggest that when researchers do return results as
part of the recruitment process, they offer written and verbal explanations that clearly
describe the results within the context of likely participant conceptions of meaning.
Moreover, we suggest these results be separated from the consent form that participants are
asked to sign so that the results are not inadvertently hidden within the form.
Research Agenda
The contributions of this study lie in data that are drawn from the TGFβ1 follow-up study’s
use of patient-participants as well as healthy volunteers. Given our small sample size, and
non-random recruitment from a larger number of participants in the TGFβ1 study, findings
of similarity as well as differences must be interpreted with caution. We believe that similar
findings, when differences might otherwise have been expected, are quite suggestive, and
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that the striking differences related to patient-participant versus healthy volunteer status
merit further investigation.
Special note should be made regarding the recruitment information from the TGFβ1 study;
prospective participants were told about categorical genetic inclusion criteria (e.g., that
eligibility was based on having either the TT or CC variant) but were not given their
individual results. This type of genotype-driven research recruitment raises additional
important research questions. How does provision of aggregate or categorical genetic
information compare to the circumstance of return of individual genetic research results?
How should researchers approach participants’ requests for specific rather than categorical
results? In our interviews, most people did not recall being provided categorical research
results during recruitment. When we showed respondents the genetic inclusion criteria at the
end of the interview, most were confused by this information, and some biobank participants
wondered about possible implications for their health or reproductive decision-making. Are
there other circumstances in which such genetic inclusion criteria might present more
concerns? Are there better ways to offer research results, taking advantage of both research
and lay perceptions of utility?
Other important questions remain that should be the subject of future research. For example,
do patient-participants with a medical condition without an obvious genetic basis perceive
the meaning of results differently than these CF participants who have known about their
condition and its genetic basis for most of their lives? Data from our larger study suggest
they do (Namey & Beskow, 2011; Tabor et al., 2011), and merit further exploration.
Educational Implications
In addition to the implications suggested by the results from our cross-site study (Beskow et
al., 2011), it is important to recognize that genotype-driven research recruitment may
increasingly target individuals who participate in biobanks or genetic registries. These
biobanks will have tremendous variation in the populations they recruit (ranging from
disease specific to general population), consent they employ, and oversight regarding access
to samples and data. In all cases, it is important for researchers and IRBs to be aware of the
various contextual factors associated with the research study and plan their recruitment
procedures (including the decision about disclosure of results) accordingly.
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Table 1
Respondent Demographics.
Cystic Fibrosis (CF) Participants (N=9) Biobank Participants (N=15)
Age Range (years) 24–50 25–57
 Mean Age (years) 32 38
Gender
 Male 6 9
 Female 3 6
Highest Level of Education
 Some College 3 0
 4-Year College Degree 3 5
 Graduate/Professional Degree 3 10
J Empir Res Hum Res Ethics. Author manuscript; available in PMC 2012 June 28.
